Updated:
New Jersey Health Foundation
New Jersey Health Foundation was established in 2002 as a nonprofit focused on advancing health-related research and education through a grantmaking model.
New Jersey Health Foundation
New Jersey Health Foundation was established in 2002 as a nonprofit focused on advancing health-related research and education through a grantmaking model. James M. Golubieski serves as President and CEO. The foundation absorbed the University of Medicine & Dentistry of New Jersey Foundation, positioning itself as a financial conduit for the state's academic medical innovation infrastructure. The foundation deploys capital across a spectrum that includes venture capital, early-stage seed investments, and growth equity, primarily targeting startups in the biotech and healthcare services sectors. Its structural edge lies in the Foundation Venture Capital Group, a wholly owned vehicle designed to launch new companies from university-owned intellectual property. The geographic focus is centered on North America, with a dense concentration in New Jersey's research corridor. Golubieski's simultaneous role on the Board of Trustees for BioNJ reinforces a direct sourcing pipeline into local life science deal flow. The late George F. Heinrich, who passed away in 2025, co-led the foundation in its formative years as Vice Chairman and CEO. The governance structure pairs a long-tenured operational executive with an experienced board, including Chairman Dean Janeway, former President of Wakefern Food Corporation. The foundation maintains a $209 million asset base (Altss estimate) alongside a claimed interest in a Neiman Marcus Group Liquidating Trust Claim, a non-standard holding for a mission-driven endowment. Unlike a standard private foundation that writes checks into third-party funds, NJHF built an in-house venture arm to incubate companies at the intersection of academic discovery and market application. This architecture gives it direct control over the translation of research grants into portfolio assets, a structural differentiator that blurs the line between pure philanthropy and strategic venture formation.
General information
Firm type
Endowment / Foundation
Year founded
2002
Location
Region
North America
Country
United States
City
Princeton
Corporate office
155 Village Blvd, Suite 130, Princeton, NJ 08540, United States
Principals
James M. Golubieski
President and CEO
Dean Janeway
Chairman of the Board
Sandra Brown Sherman
Secretary and Legal Counsel
Sector focus
Frequently asked questions
Who leads investment decisions at the New Jersey Health Foundation?
James M. Golubieski, the foundation's President and CEO, drives the investment strategy. He also heads the Foundation Venture Capital Group, the subsidiary that turns academic research into portfolio companies. The late George F. Heinrich co-led the entity until his passing in 2025.
How is the foundation's venture capital activity separated from its grantmaking?
The grantmaking flows through the primary nonprofit structure, while seed and startup investing runs through the Foundation Venture Capital Group. This wholly owned subsidiary permits direct equity stakes in newly formed companies, a structure unusual for a health-focused foundation that is otherwise a philanthropic asset owner.
Does New Jersey Health Foundation participate in fund commitments or only direct deals?
The foundation's primary operating model targets direct, early-stage investments in biotech and healthcare ventures emerging from university research. Its known structure does not emphasize external fund commitments, focusing instead on creating and capitalizing startups through its in-house venture group.
What is the foundation's connection to the University of Medicine & Dentistry of New Jersey?
New Jersey Health Foundation is the parent entity of the UMDNJ Foundation, which was absorbed into its structure. This places NJHF at the center of a legacy academic medical network, giving it privileged access to intellectual property and spinout opportunities from one of the state's historically largest health sciences research engines.
What type of biotech companies does the foundation target?
The firm targets very early-stage life science companies, from seed to startup phases, with a specific focus on translating university-owned intellectual property into operational companies. While the portfolio itself is not publicly listed, the sourcing strategy is tightly bound to New Jersey's academic medical research institutions and the local BioNJ trade ecosystem.
What is the primary source of the foundation's capital?
The New Jersey Health Foundation operates as a nonprofit asset owner. The precise origin of its endowment or corpus is not publicly detailed by the organization, but its structural identity is that of a foundation supporting health research and education within New Jersey rather than a single-family source.
Why does the foundation hold a claim related to Neiman Marcus Group?
The foundation's disclosed assets include a Neiman Marcus Group Liquidating Trust Claim, a remnant of the retailer's 2020 bankruptcy. This non-standard holding likely entered the portfolio as a distressed or special-situations claim purchase rather than a strategic life science allocation, reflecting opportunistic balance sheet management alongside the core health-tech mission.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: